在六名患者的慢性复发性Clostridium difficile腹的细菌疗法
1Department of Clinical Microbiology, Rigshospitalet, Statens Seruminstitut, Denmark.
Lancet (London, England)
|May 27, 1989
概括
恢复有益的肠道细菌,特别是Bacteroides物种,可以有效地治疗由Clostridium difficile引起的慢性腹. 这种便微生物种移植方法恢复了健康的肠道微生物群,防止了复发的C. difficile感染.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
背景情况:
- 慢性复发性腹通常是由于Clostridium difficile感染引起的.
- 特定肠道细菌在预防C. difficile复发中的作用尚未完全理解.
研究的目的:
- 研究便微生物群移植在治疗慢性复发性Clostridium difficile腹中的疗效.
- 为了确定涉及治疗效果的特定细菌物种.
主要方法:
- 在6名患者的直肠灌注同类便或定义的细菌混合物.
- 在治疗前和治疗后,便分析Clostridium difficile,其毒素和细菌组成.
- 在体外研究评估细菌相互作用.
主要成果:
- 用细菌混合物治疗导致C. difficile及其毒素的迅速消除.
- 在治疗后观察到Bacteroides物种的成功殖民.
- 实验室内测试显示,某些细菌对C. difficile生长有抑制作用.
结论:
- 由于没有Bacteroides物种,可能会使个体易患慢性复发性C. difficile腹.
- 通过便微生物群移植恢复Bacteroides物种可以防止C. difficile的殖民和复发.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...


